Emerging Microbes and Infections (Dec 2022)

Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters

  • Melanie Rissmann,
  • Danny Noack,
  • Debby van Riel,
  • Katharina S. Schmitz,
  • Rory D. de Vries,
  • Peter van Run,
  • Mart M. Lamers,
  • Corine H. Geurts van Kessel,
  • Marion P. G. Koopmans,
  • Ron A. M. Fouchier,
  • Thijs Kuiken,
  • Bart L. Haagmans,
  • Barry Rockx

DOI
https://doi.org/10.1080/22221751.2022.2095932
Journal volume & issue
Vol. 11, no. 1
pp. 1778 – 1786

Abstract

Read online

The Omicron BA.1 (B.1.1.529) SARS-CoV-2 variant is characterized by a high number of mutations in the viral genome, associated with immune escape and increased viral spread. It remains unclear whether milder COVID-19 disease progression observed after infection with Omicron BA.1 in humans is due to reduced pathogenicity of the virus or due to pre-existing immunity from vaccination or previous infection. Here, we inoculated hamsters with Omicron BA.1 to evaluate pathogenicity and kinetics of viral shedding, compared to Delta (B.1.617.2) and to animals re-challenged with Omicron BA.1 after previous SARS-CoV-2 614G infection. Omicron BA.1 infected animals showed reduced clinical signs, pathological changes, and viral shedding, compared to Delta-infected animals, but still showed gross- and histopathological evidence of pneumonia. Pre-existing immunity reduced viral shedding and protected against pneumonia. Our data indicate that the observed decrease of disease severity is in part due to intrinsic properties of the Omicron BA.1 variant.

Keywords